New combo therapy targets tough cancers in early trial

NCT ID NCT06946225

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times

Summary

This early-stage trial tests a new treatment combining two experimental therapies (IMA203 and mRNA-4203) for people with advanced melanoma or synovial sarcoma that has spread or can't be removed. The main goal is to check safety and find the best dose. About 15 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Email: •••••@•••••

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Email: •••••@•••••

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.